NGS Testing Challenges and Considerations in NSCLC
Expert perspectives on next-generation sequencing for patients with non–small cell lung cancer, highlighting challenges and the differences between RNA and DNA testing.
EP: 1.Biomarker Testing in Non–Small Cell Lung Cancer
EP: 2.NSCLC: Molecular Testing in the Metastatic Setting
EP: 3.NGS Testing Challenges and Considerations in NSCLC
EP: 4.Frontline Treatment for EGFR-Mutated Lung Cancer
EP: 5.FLAURA2: Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
EP: 6.MARIPOSA: First-Line Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC
EP: 7.Second-Line Treatment of Patients With EGFR-Mutated NSCLC
EP: 8.Treatment Landscape for NSCLC With EGFR Exon 20 Insertion Mutations
EP: 9.NSCLC with EGFR Exon 20 Insertions: Updated Data from PAPILLON
EP: 10.Unmet Needs and Future Perspectives on the Treatment of EGFR-Mutated NSCLC
EP: 11.Preferred Treatment Options for EGFRMutated Exon 20 Insertion+ NSCLC
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
